ページ2 - 最高の扁桃癌医師 - トップ65名の医師

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

プロフェッサー ネジデット・ユシュケントは、アンカラ大学医学部を卒業しました。彼はアンカラGATA医学校で内科医学のレジデンシー研修を修了しました。彼はアメリカのテキサス州ダラスで医療用腫瘍学および血液学の臨床フェローシップ研修を行いました。トルコで最初の移植を実施した骨髄移植チームに参加しました。異なる時期に、彼はロンドンのウェストミンスター病院 チャリングクロス、ハマースミス、ロイヤル フリー、ユニバーシティ カレッジ 病院で長期間の客員講師を務め、スイスのバーゼル カントン病院でも講義しました。欧州医学腫瘍学会（ESMO）によって主催された試験に合格し、彼はヨーロッパ医学腫瘍学証明書を取得しました。トルコ医学腫瘍学会の7人の創設会員の1人として、プロフェッサー ユシュケントはトルコ腫瘍学グループ（TOG）の創設者でもありました。

学歴

大学 

アンカラ大学医学部, アンカラ 1971 

専門教育 

GATA 医学校, アンカラ 1979 
 

ワドレー分子医学研究所, グランビル・モートンがん病院, 医療用腫瘍学および血液学のサブスペシャリティ, 1982

助教

GATA 医学校, 医療用腫瘍学クリニック, アンカラ 1984 

准教授 

GATA 医学校, 医療用腫瘍学クリニック, アンカラ 1989 

教授 

GATA, 医療用腫瘍学および血液学クリニック, イスタンブール 2001

専門分野

• 乳がん
• 胃腸がん
• 肺がん
• リンパ腫
• 骨髄腫
  
  所属機関
  
  トルコ医学腫瘍学会
• トルコ血液学会
• 肺がん学会
• 免疫腫瘍学会
• 神経腫瘍学会
• 乳がん学会
• イスタンブール胃腸がんグループ
• イスタンブールリンパ腫グループ
• イスタンブール骨髄腫グループ
• 欧州医学腫瘍学会（ESMO）
• 米国臨床腫瘍学会

チェリンスキー教授は、腫瘍内科学およびがん免疫療法における世界的なリーダーであり、44年の経験以上にわたり現代のがん治療の発展に貢献してきました。現在は、ウィーナー・プリーヴァートクリニックの国際腫瘍センターを率いています。

• ウィーン総合病院 腫瘍科臨床部門 元部門長
• ウィーン包括的がんセンター（CCC）の創設者および元所長
• 患者の腫瘍生物学に基づいた個別化がん治療の専門家
• 中央ヨーロッパ協同腫瘍グループ（CECOG）元会長
• 国際腫瘍学における正教授および著名な講師

ケイル教授は2004年にジュリアス・マクシミリアン大学ヴュルツブルクで医学の学位を取得し、優秀な成績で卒業しました。

彼の専門的なキャリアはハンブルクで始まり、そこで彼は初期の経験を積み、ハンブルク・アルトンクリニックの放射線科で博士論文を見事に防衛しました。当時はドイツやヨーロッパで最も進んだ放射線学センターの一つでした。 

2006年、ケイル教授はアーヘン大学病院に移り、著名なロルフ・W・ギュンター教授の指導の下で知識とスキルを深めました。

ギュンター教授のチームに所属し、その後クリニックディレクターであるクリスチャン・K・クール教授の指導の下、セバスチャン・ケイル教授は超音波やCT、MRIのような現代的なイメージング技術を使用し、複雑な医療介入を成功裏に行いました。

 2010年には、診断および介入放射線学クリニックの主要医師に任命され、2016年から2022年までクール教授が指導するクリニックの主要医師を務めました。

2022年以降、ケイル教授はソリンゲン学術病院の診断及び介入放射線クリニックの主任医師を務めています。

専門分野:

• 断面画像診断: 体全体の領域と病態のMRIとCT
• 介入放射線学サービスのフルレンジ
• 超音波検査、X線診断および蛍光透視
• 乳房診断

フォックス・ヴィオラ博士は、BKZゾーリンゲン血液腫瘍科・緩和医療科の主任医師です。同クリニックは、認定された集学的腫瘍センターです。フォックス博士は、ドイツおよびヨーロッパにおける腫瘍性疾患の薬物療法の第一人者であり、15年以上の臨床経験を有しています。

同博士は、ドイツ腫瘍学・血液腫瘍学会（GDHO）、ドイツ医師会、およびアメリカがん研究学会に所属しています。また、分子生物学の研究にも従事しており、その研究成果はがん治療および分子診断の発展に貢献しています。

主な専門領域は、化学療法、免疫療法、分子標的療法、および放射線療法です。フォックス博士は、革新的な治療法と患者への細やかな配慮で知られています。その取り組みにより、高い治癒率を達成し、同僚からの高い評価を得ています。

エルケ・イェーガー教授は、サルコーマ（肉腫）の第一人者であり、フォーカス誌のランキングによるドイツ最高峰の腫瘍専門医の一人です。

• ノルトヴェスト・クリニック 腫瘍内科・血液内科部長
• 41年の経験 の腫瘍学における診療経験
• 複雑な癌症例を専門とする

Director of Radiotherapy Institute Oncology Division

Professor, Oncologist

Univ. Prof. Dr. ウォルフガング・ケストラーは、オーストリアの著名な医学的腫瘍学者および内科医であり、乳がん、婦人科悪性腫瘍、および標的がん治療の専門知識で国際的に認められています。臨床、学術、研究の経験が20年以上にわたり、彼はオーストリアにおける個別化がん治療の最前線の権威の一人となりました。

彼はウィーン大学で医学を学び、1990年代に卒業し、その後ウィーン医科大学で内科および医学的腫瘍学のレジデンシーを修了しました。キャリアの初期には、彼は先進的な腫瘍学者と共に標的療法と個別化医療の開発に従事し、これは後の彼の多くの研究に影響を与える分野となりました。

   1990年代 – ウィーン総合病院（AKH）での内科および腫瘍学の研究およびレジデンシーを修了しました。

   2000年代 – 固形腫瘍腫瘍学に特化し、乳がんや婦人科がんに焦点を当て、標的療法に関する初期の臨床試験に貢献しました。

   2010年代 – ウィーン医科大学の准教授および腫瘍学の臨床部門の副主任に任命され、分子腫瘍学の推進に貢献しました。

   現在 – ウィーン私立クリニックで上級コンサルタントとして勤務し、ウィーン医科大学での学術活動を続け、個別化された全身がん治療、免疫療法、および転位がん研究に注力しています。

ケストラー教授の研究関心には、バイオマーカーの開発、腫瘍生物学、および標的薬剤への耐性メカニズムが含まれており、正確な腫瘍学における新しい治療戦略の設計に貢献しています。彼の科学研究は主要な国際雑誌に掲載されており、彼はヨーロッパの腫瘍学ネットワークに積極的に参加し続けています。

診断の正確さ、臨床的共感、革新的な考え方で知られるケストラー教授は、科学的進歩と慈悲深い患者ケアを組み合わせた個別化がん医学の未来を体現しています。

この医師は、乳がん、肺がん、消化器系がんの治療を専門とする腫瘍学者です。現在、医師はIstinye Liv University Hospitalで診療を行っています。<\/p>

多くの著名な機関でのキャリアを持ち、医師はMalatya State Hospitalで内科専門医として、Ankara Oncology Clinicで医師として、Erzurum Regional Training and Research Hospitalの腫瘍学部門のメンバーとして勤務してきました。<\/p>

医師はSelcuk Universityの医学部を卒業し、2016年に准教授の称号を取得しました。<\/p>

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Education

• 1986-1989, Bursa High School, Bursa, Turkey
• 1989-1995, Istanbul University, Istanbul School of Medicine, Turkey
• 1999-2003, (Residency) Kadir Has University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey
• 2015, (Associate Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Experience

• 1995-1999, Şişli Florence Nightingale Hospital, Istanbul, Cardiology Department
• 2003, Gayrettepe Florence Nightingale Hospital, Istanbul, Department of Radiation Oncology
• 2015, (Associate Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2021, (Professor in Radiation Oncology) Demiroglu Bilim University, Department of Radiation Oncology, Istanbul, Turkey
• 2024, Istanbul Medipol University, Department of Radiation Oncology, Istanbul, Turkey

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Professor Kyzas completed his PhD thesis in H&N Cancer with Honours (Αριστα), producing several highly cited influential publications. He has published > 70 scientific papers in high impact journals and has > 6000 citations.

Following his studies, Professor Kyzas has undertaken postgraduate training in the UK and was successful in securing a very competitive training post in the UK Higher Specialty Training Programme for Oral and Maxillofacial Surgery. He was trained in some of the biggest University Teaching hospitals in the North West of the UK. He has been awarded the Certificate of Completion of Training (CCT) in Oral and Maxillofacial Surgery by the General Medical Council (GMC). Subsequently, he was successful in securing one of the very few and prestigious UK-wide Training Interface (TIG) Fellowships in Head and Neck Surgical Oncology. He has successfully completed his fellowship and was awarded the subspecialty of Head and Neck Surgery by the Joint Committee of Surgical training (JCST).

In 2014 he has been appointed as a permanent substantive Consultant in Oral and Maxillofacial/Head and Neck Surgery in Manchester. He has treated hundreds of patients with Head and Neck cancer, offering state of the art major ablative and reconstructive surgery. He specialises in microvascular free tissue transfer and he has introduced and developed the 3D printer – personalised planning (PSP) reconstructive surgery in his hospital. He led his unit to become a reference centre by having the highest number of successful 3D PSP cases in the UK. Besides head and neck cancer, Professor Kyzas offers treatment to patients with facial skin cancer, oral and maxillofacial trauma, dentoalveolar surgery, orthognathic surgery, salivary gland diseases, facial cosmetic surgery, surgery of the temporomandibular joint, and anything else within the broad spectrum of Oral and Maxillofacial Surgery. He has performed many thousands of surgical procedures and has vast experience in any oral and maxillofacial condition. He has a special interest in the use of laser for oral pathologies and he is the Principal Investigator for an international trial examining the effectiveness of Transoral Laser resection in Ηead and Νeck Cancer. He is a certified microvascular surgeon and has accreditation in advanced trauma life support (ATLS).

Just before the covid pandemic, Professor Kyzas was presented with a unique opportunity to lead on the development of a Head and Neck Cancer Service in Lancashire. Professor Kyzas and his team managed to establish the service within months, and throughout the challenging covid period. The ELHT H&N Unit now produces oncological outcomes that compare favourably with any major H&N unit worldwide. Professor Kyzas has been appointed as the Clinical Director for all cancer services in ELHT, covering population of > 1M people.

In 2021, Professor Kyzas has been awarded the highly prestigious Bronze National Clinical Excellence Award for his overall services in the NHS. He was the youngest consultant to achieve this award and the only Cypriot OMFS surgeon ever to be considered for one.

Professor Kyzas has a long history of involvement in medical research. In 2007 he has completed his PhD thesis which has resulted in several highly cited publications in some of the most prestigious medical journals. He has participated in international collaborations for the improvement of medical research (http://progress-partnership.org/publications) and some of his papers have had a significant impact in improving research methodology. He has given several invited international lectures, and he has presented in national and international conferences. He has been a panel member for the selection committees for trainees in every level in oral and Maxillofacial Surgery in the UK. He is a regular peer-reviewer for many medical journals. He is the Lead trainer for the TIG H&N fellowship for his hospital and the Research Lead for his Deanery. He participates actively in Clinical Research, and he is the Principal Investigator for many clinical trials. He is a faculty member for the «Head and Neck resection tactics and free flap» course run by the Royal College of Surgeons of Edinburgh. He offers themed training in Head and Neck Oncological Surgery to medical students. In 2018 he was awarded the «Surgical Educator Excellence Award» by Health Education North West (HEENW). In the same year, he was nominated as doctor of the year in Northern Care Alliance.

Professor Kyzas is the Chief Investigator of the MANTRA trial, a UK multicentre RCT with multimillion pounds NIHR funding, launched in July 2023. This is the biggest randomised controlled trial ever to be performed in the specialty of OMFS.

As a result of his outstanding clinical and research/academic achievements, Professor Kyzas has been appointed as a visiting Professor in OMFS H&N Surgery at Edge Hill University

In 2018 Professor Kyzas was elected as the Deputy Editor for the British Journal of Oral and Maxillofacial Surgery (BJOMS). In January 2024, Professor Kyzas started his role as Editor in Chief for the BJOMS. This is the first time that a Greek Cypriot has ever been chosen for this highly prestigious role. Professor Kyzas sits in the council of the British Association of Oral and Maxillofacial Surgeons (BAOMS).

Professor Kyzas is a fully accredited medical expert witness and has provided hundreds of medical expert negligence reports (πραγματογνώμονας). In June 2024, Professor Kyzas has completed his Degree in Law with Honours (Άριστα), becoming a member of a very prestigious club of medical professionals with an active interest and certified knowledge in medicolegal practice.

Professor Kyzas is a fully accredited Oral and Maxillofacial Surgeon on the specialist register of the General Medical Council (GMC) UK, the Cyprus Medical Association (Cyprus), and the Cyprus Dental Association (Cyprus). In addition, he is also fully recognised and registered as Oral Surgeon by the General Dental Council (GDC) UK. He is a fellow of the Royal College of Surgeons (FRCSEd), member of the Faculty of Surgical Trainers (MFSTEd), fellow of the British Association of Oral and Maxillofacial Surgeons (BAOMS), member of the Hellenic Society of Head and Neck Oncology (HeSHNO) and member of the European Association of Craniomaxillofacial Surgery (ECAMFS).

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.